Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 04:40PM GMT
Release Date Price: $49.95 (+5.31%)
Unidentified Analyst

Good morning. Thank you all for joining today my name is [Steve] (inaudible) and I'm a member of the JPMorgan Healthcare Investment Banking team.

It is my great pleasure to introduce Ken Mills, President and CEO of REGENXBIO. (Operator Instructions) Ken?

Kenneth T. Mills
REGENXBIO Inc. - CEO, President & Director

Thank you, [Steve], and good morning, everyone. Thanks to the organizers and JPMorgan for inviting myself and REGENXBIO to present today at the conference. Hope everyone is doing well and is safe in this new year. We'll be providing some forward-looking statements in this presentation. The references to additional information about REGENXBIO that are on file with the SEC can be found on Slide 2 of the accompanying presentation.

But I'm going to start my presentation with Slide 3 and describe REGENXBIO, its mission, our focus, which is patient-focused, seeking to improve the lives through the curative potential of gene therapy as many patients and families as possible. We have multiple ongoing clinical studies at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot